Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Vishal K Gupta, MD, Paul White, MD, Vaishali Sanchorawala, MD, Karen Quillen, MD MPH, Shayna Sarosiek, MD, Dina Brauneis, NP, John Mark Sloan, MD

Blood (2018) 132 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2018-99-110230

Published: 2018

Journal Articles

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Vishal K Gupta, MD, Dina Brauneis, NP, Anthony C Shelton, RN, Karen Quillen, MD MPH, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2018-99-111551

Published: 2018

Journal Articles

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Robert Meehan, MD, David Seldin, MD, John Mark Sloan, MD, Karen Quillen, MD MPH, Dina Brauneis, ANP, Anthony C Shelton, RN, Vaishali Sanchorawala, MD

Blood (2014) 124 (21): 5906.

https://doi.org/10.1182/blood.V124.21.5906.5906

Published: 2014

Journal Articles

Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease

Jacqueline N. Milton, PhD, Allison E. Ashley-Koch, PhD, Melanie E. Garrett, MS, Karen L. Soldano, B.S., Eugene P. Orringer, MD, Paola Sebastiani, PhD, Daniel A. Dworkis, MD PhD, Karen Quillen, MD MPH, Martin H. Steinberg, MD, Marilyn J. Telen, MD

Blood (2014) 124 (21): 762.

https://doi.org/10.1182/blood.V124.21.762.762

Published: 2014

Journal Articles

Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Amitabh Gautam, MD, Jean M Francis, MD

Blood (2013) 122 (21): 4728.

https://doi.org/10.1182/blood.V122.21.4728.4728

Published: 2013

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

Acquired Glanzmann's Thrombasthenia Associated with Hodgkin Lymphoma: Rapid Reversal of Functional Platelet Defect with Chemotherapy Despite Persistence of a Glycoprotein Iib/Iiia Auto-Antibody

Vinod Raman, MD, Karen Quillen, MD, MPH, John Mark Sloan, MD

Blood (2012) 120 (21): 4656.

https://doi.org/10.1182/blood.V120.21.4656.4656

Published: 2012

Journal Articles

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 2019.

https://doi.org/10.1182/blood.V120.21.2019.2019

Published: 2012

Journal Articles

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Saulius Girnius, M.D., David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, John L Berk, MD, Frederick L Ruberg, MD, Hans Meier-Ewert, MD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2043.

https://doi.org/10.1182/blood.V118.21.2043.2043

Published: 2011

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

NARROW

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease

Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Acquired Glanzmann's Thrombasthenia Associated with Hodgkin Lymphoma: Rapid Reversal of Functional Platelet Defect with Chemotherapy Despite Persistence of a Glycoprotein Iib/Iiia Auto-Antibody

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only